[
    [
        {
            "time": "2017-unknown",
            "orginal_text": "2017全年企业上市总费用195亿募集资金总额为2105亿",
            "features": {
                "keywords": [
                    "2017全年",
                    "企业上市",
                    "总费用",
                    "募集资金"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "2017全年企业上市总费用195亿募集资金总额为2105亿",
            "scores": {
                "News_content": "2017全年企业上市总费用195亿募集资金总额为2105亿",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-01-01",
            "orginal_text": "【医药】江琦：医药生物行业2018年1月月报：2018是政策落地大年，看好创新药、高品质仿制药、医疗服务三大方向-增持-0101",
            "features": {
                "keywords": [
                    "医药生物",
                    "2018年",
                    "政策落地",
                    "创新药",
                    "高品质仿制药",
                    "医疗服务"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "【医药】江琦：医药生物行业2018年1月月报：2018是政策落地大年，看好创新药、高品质仿制药、医疗服务三大方向-增持-0101",
            "scores": {
                "News_content": "【医药】江琦：医药生物行业2018年1月月报：2018是政策落地大年，看好创新药、高品质仿制药、医疗服务三大方向-增持-0101",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        }
    ]
]